top of page
Asset 3

Meningococcal meningitis is a bacterial disease caused by Neisseria meningitidis. It can cause an infection of the lining membrane of the brain and spinal cord. It can result in serious complications.(1)

Asset 6_edited_edited.jpg

5

There are 5 types of Meningococcal meningitis (meningococcal A, C, W, Y, and B#)of particular importance due to their potential to cause disease for which vaccines are available in Saudi Arabia.(5,6)

Asset 11
Asset 8
Asset 112edited

Neisseria meningitidis is a bacteria that causes Meningococcal meningitis.(1)

About 1 in 10 people carry this bacteria in
the back of their nose and throat without
facing any illness. These people are called carriers.
(1)

AdobeStock_321820758.jpeg
Asset 16
face


- Meningococcal meningitis is spread through respiratory     secretions such as through spit and saliva.(1) 
- Generally, it takes close or lengthy contact to
   spread this bacteria (for example, coughing or
   kissing).
(1)

AdobeStock_321820758.jpeg
Asset 24

The most common symptoms include :(1)

  • Fever

  • Headache

  • Stiff neck

Asset 25
Asset 24

There are often additional symptoms, such as:(1)

  • Nausea

  • Vomiting

  • Photophobia (eyes being more sensitive to light)

  • Altered mental status (confusion)

Asset 23
Asset 23
Asset 22

While early signs and symptoms are similar to flu, the rapid transition of
these into serious complications are what
distinguish it from other diseases.
(2)

Asset 22
AdobeStock_548869584.jpeg
Asset 29

Anyone can get Meningococcal meningitis , but certain people are at increased risk (1,7-9)

MASS GATHERINGS

  • Mass gathering can increase risk of
    Meningococcal meningitis disease.

Asset 33

MEDICATIONS

  • People who receive complement inhibitors are at increased risk
    for meningococcal meningitis disease.

Asset 32

MEDICAL CONDITIONS

Asset 30
  • Persistent complement.
    component deficiencies.

  • Functional and anatomic asplenia

  • HIV infection.

Asset 31

AGE

  • Children younger than 1 year of age.

  • Teens and young adults ages 16
    through 23 years old.

  • Adults 65 years and older.

Asset 44edited
AdobeStock_548869584.jpeg
  • Maintaining hygiene and
    not sharing cups,
    toothbrushes and others.

  • Wearing Masks, and
    covering the mouth and
    nose when sneezing

  • Vaccination*

*Refer back to MOH preventive measures recommendation and consult you doctor or licensed pharmacist on the best ways to get fully protected

AdobeStock_548869584.jpeg
Asset 49

Meningococcal 

A, C, W, Y vaccine

Meningococcal 

B vaccine#

*Refer back to MOH preventive measures recommendation and consult you doctor or licensed pharmacist on the best ways to get fully protected

Asset 6_edited_edited.jpg
Doseperoid
Dose
Asset 3

Meningococcal
B vaccine

You're now 
FULLY PROTECTED
against meningococcal
meningitis for Hajj

Meningococcal
A, C, W, Y vaccine

Meningococcal
B vaccine
#

There are 5 types of Meningococcal meningitis
(meningococcal A, C, W, Y, and B) of particular importance due
to their potential to cause disease for which vaccines are
available in Saudi Arabia
(5,6)

There are 2 types of vaccines available in Saudi Arabia:(6) 

• Meningococcal ACWY vaccine
• Meningococcal B vaccine

Asset 68.png
Asset90
Asset 3

PLANNING FOR HAJJ?

It takes 2

vaccines to be

FULLY PROTECTED?*

against all 5 types of 

Meningococcal Meningitis

*If vaccination is recommended

Consult your doctor about being fully protected*
against all types of meningococcal meningitis

*Refer to MOH preventive measures recommendation and consult your doctor or licensed       pharmacist on the best ways to get fully protected

  References: 1. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/ Last accessed January 2 2024. Hovmand N,
Christensen HC, Lundbo LF, et al. Nonspecic symptoms dominate at rst contact to emergency healthcare services among cases with
invasive meningococcal disease. BMC Fam Pract. 2021 Nov 240:(1)22;30. doi: 10.1186/s9 8-01585-021-12875.
2. https://sdi.sfda.gov.sa/Home/DrugSearch?textFilter=MENINGITIDIS - accssed Jan 2024

This Awareness Content is developed by GSK and
intended for Saudi Arabia residents only.


Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor.
GlaxoSmithKline Export Limited, Saudi Arabia

References:1. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/ Last accessed January 2 2024. Hovmand N,Christensen HC, Lundbo LF, et al. Nonspecifc symptoms dominate at first contact to emergency healthcare services among cases withinvasive meningococcal disease. BMC Fam Pract. 2021 Nov 240:(1)22;30. doi: 10.1186/s9 8-01585-021-12875.
2. https://sdi.sfda.gov.sa/Home/DrugSearch?textFilter=MENINGITIDIS - accssed Jan 2024

Blackgold_bg.png

References:

  1. Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/ Last accessed January 2024

  2. Hovmand N, Christensen HC, Lundbo LF, et al. Nonspecific symptoms dominate at first contact to emergency
    healthcare services among cases with invasive meningococcal disease. BMC Fam Pract. 2021 Nov 30;22(1):240. doi:
    10.1186/s12875-021-01585-8

  3. https://www.stats.gov.sa/system/tdf/file_manger/Hajj%20Report%201444H-EN_compressed-2.pdf?file=1&type=node
    &id=145224&force=0

  4. Memish ZA, Al-Tawfiq JA, Almasri M, et al. Neisseria meningitidis nasopharyngeal carriage during the Hajj: A cohort
    study evaluating the need for prophylaxis. Vaccine. 2017 Apr 25;35(18):2473-2478. doi:
    10.1016/j.vaccine.2017.03.027

  5. World Health Organization (WHO), 2018. Meningococcal meningitis. Factsheet no. 141 [last accessed Feb 2021]

  6. https://sdi.sfda.gov.sa/Home/DrugSearch?textFilter=MENINGITIDIS - accssed Jan 2024

  7.  Muttalif AR . Inf Infect Dis Ther 2019

  8. Borrow R. Travel Med Infect Dis. 2009;7:219-252

  9. Lingappa JR, et al. Emerg Infect Dis. 2003;9:665-67

  10.  Ministry Of Health Saudi Arabia. Available at:
    https://www.moh.gov.sa/en/awarenessplateform/VariousTopics/Pages/Meningitis.aspx. Last accessed February
    2024

This Awareness Content is developed by GSK and
intended for Saudi Arabia residents only.


Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor.
GlaxoSmithKline Export Limited, Saudi Arabia

 للإبلاغ عن ظهور أية  آثار جانبية(أثر جانبي) يرجى التواصل مع الهيئة العامة للغذاء و الدواء السعودية على الرقم 19999،رقم الترخيص (50-SFDA-45)

GSK أنشأ هذا المحتوى التوعوي،ويستهدف المقيمين بالممكلة العربية السعودية فقط

GSK يملك العلامة التجارية أو يحمل ترخيصها.
مجموعة شركات ©GSK 2024 أو حامل ترخيصها.
جلاسكو سميث كلاين المحدودة،الممكلة العربية السعودية

NP-SA-MNU-WCNT-240001 / Date of preparation: April 2024

NP-SA-MNU-WCNT-240001 / Date of preparation: April 2024

bottom of page